ALXO
ALXO clinical trials: ALX ONCOLOGY HOLDINGS INC
Every trial on ClinicalTrials.gov where ALX ONCOLOGY HOLDINGS INC is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 13
- Trials linked
- 9
- As lead sponsor
- 4
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
ALXO on the catalyst calendar · ALXO registry changes
- Primary completion Dec 2027Sponsor estimatePhase 2NCT07007559ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast CancerALX Oncology Inc. · Breast Cancer, MetastaticRecruitingALXOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 24, 2024ActualPhase 2/Phase 3NCT05002127A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)ALX Oncology Inc. · Gastric CancerCompletedALXOLeadLLYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2027Sponsor estimatePhase 1NCT07085091A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid TumorsALX Oncology Inc. · NSCLC (Advanced Non-small Cell Lung Cancer)RecruitingALXOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 3, 2025ActualPhase 2NCT04675333Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma...ALX Oncology Inc. · Head and Neck CancerActive, not recruitingALXOLeadMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 3, 2025ActualPhase 2NCT04675294Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)ALX Oncology Inc. · Head and Neck CancerActive, not recruitingALXOLeadMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 1, 2022ActualPhase 1NCT03013218A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)ALX Oncology Inc. · Metastatic CancerCompletedALXOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 27, 2025ActualPhase 1NCT05524545A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07)ALX Oncology Inc. · Bladder CancerCompletedALXOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 17, 2025ActualPhase 1NCT04417517A Study of Evorpacept (ALX148) With Azacitidine for Higher Risk Myelodysplastic Syndrome (ASPEN-02)ALX Oncology Inc. · Higher Risk Myelodysplastic SyndromesTerminatedALXOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 5, 2023ActualPhase 1NCT04755244A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05)ALX Oncology Inc. · Acute Myeloid LeukemiaTerminatedALXOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 30, 2030Sponsor estimatePhase 1/Phase 2NCT05868226PRE-ISPY Phase I/II Oncology Platform ProgramQuantumLeap Healthcare Collaborative · HER2-positive Breast Cancer
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 30, 2024ActualPhase 2NCT05167409Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal CancerUniversity of Colorado, Denver · Microsatellite Stable Metastatic Colorectal Cancer
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 13, 2026ActualPhase 2NCT05467670Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant...Alexander B Olawaiye, MD · Ovarian CancerActive, not recruitingMRKCollaboratorALXOCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 29, 2025ActualPhase 1/Phase 2NCT05027139A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing CancerJazz Pharmaceuticals · HER2-expressing CancersCompletedJAZZLeadALXOCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 13 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner